- Home
- SXTP vs NCNA Comparison
SXTP vs NCNA Comparison
Compare SXTP & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- NCNA
- Stock Information
- Founded
- SXTP 2010
- NCNA 1997
- Country
- SXTP United States
- NCNA United Kingdom
- Employees
- SXTP N/A
- NCNA N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- NCNA Health Care
- Exchange
- SXTP Nasdaq
- NCNA Nasdaq
- Market Cap
- SXTP 4.3M
- NCNA 4.5M
- IPO Year
- SXTP 2023
- NCNA 2017
- Fundamental
- Price
- SXTP $2.32
- NCNA $0.09
- Analyst Decision
- SXTP Buy
- NCNA Buy
- Analyst Count
- SXTP 2
- NCNA 2
- Target Price
- SXTP $7.00
- NCNA $25.00
- AVG Volume (30 Days)
- SXTP 324.9K
- NCNA 319.9M
- Earning Date
- SXTP 08-13-2025
- NCNA 08-14-2025
- Dividend Yield
- SXTP N/A
- NCNA N/A
- EPS Growth
- SXTP N/A
- NCNA N/A
- EPS
- SXTP N/A
- NCNA N/A
- Revenue
- SXTP $802,323.00
- NCNA N/A
- Revenue This Year
- SXTP $95.50
- NCNA N/A
- Revenue Next Year
- SXTP $80.78
- NCNA N/A
- P/E Ratio
- SXTP N/A
- NCNA N/A
- Revenue Growth
- SXTP 118.37
- NCNA N/A
- 52 Week Low
- SXTP $1.41
- NCNA $0.03
- 52 Week High
- SXTP $35.99
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- SXTP 50.64
- NCNA 41.41
- Support Level
- SXTP $1.91
- NCNA $0.07
- Resistance Level
- SXTP $2.55
- NCNA $0.10
- Average True Range (ATR)
- SXTP 0.24
- NCNA 0.03
- MACD
- SXTP -0.00
- NCNA 0.01
- Stochastic Oscillator
- SXTP 46.09
- NCNA 25.70
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.